Rating for CLSD
Clearside Biomedical, Inc. (CLSD)
Last clearside biomedical, inc. earnings: 3/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.clearsidebio.com/investor-overview
Company Research
Source: Benzinga
Impact Snapshot
Event Time:
CLSD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLSD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLSD alerts
High impacting Clearside Biomedical, Inc. news events
Weekly update
A roundup of the hottest topics
CLSD
News
- Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, EyeGlobeNewswire
- Clearside Biomedical, Inc. (NASDAQ: CLSD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United StatesGlobeNewswire
- Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Landscape Research 2024 [Yahoo! Finance]Yahoo! Finance
CLSD
Earnings
- 11/12/24 - Beat
CLSD
Sec Filings
- 12/12/24 - Form 8-K
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- CLSD's page on the SEC website